Literature DB >> 22721546

Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study.

Olalla Caseiro1, Rocío Pérez-Iglesias, Ignacio Mata, Obdulia Martínez-Garcia, Jose Maria Pelayo-Terán, Rafael Tabares-Seisdedos, Victor Ortiz-García de la Foz, José L Vázquez-Barquero, Benedicto Crespo-Facorro.   

Abstract

BACKGROUND: Preventing relapse during the first years of illness has a critical impact on lifelong outcomes in schizophrenia. A better understanding and improvement in factors which influence relapse should diminish the risk of relapse and consequently improve the outcome of the illness.
OBJECTIVE: To identify factors associated with relapse after 3 years of a first episode in a sample of non-affective psychosis patients who are representative of clinical practice in an epidemiological catchment.
METHOD: We analyzed socio-demographic and clinical data from a cohort of patients who were treated in a specialized early intervention service and who were at risk of relapse during a 3-year follow-up. Univariate analyses, logistic regression and survival analyses were performed. The analyzed variables included gender, age at onset, duration of untreated psychosis, clinical severity at baseline, insight at baseline, premorbid functioning, substance use, family history of psychosis and adherence to medication.
RESULTS: Of the 140 patients considered to be at risk for relapse, 91 (65%) individuals relapsed at least once over the three-year period. The relapse rates at 1 year and 2 years were 20.7% and 40.7%, respectively. Adherence to medication was the only significant predictor of relapse after a three-year follow-up [hazard ratio (HR) 4.8, 95% confidence interval (CI) 2.9-7.7; p < 0.001]. Comparison of the mean time of relapse between adherent and non-adherent patients also revealed statistically significant differences (933 and 568 days, respectively). 50% of patients will relapse despite being categorized as treatment adherents.
CONCLUSION: Non-adherence to medication is the biggest predictive factor of relapse after a first episode of psychosis.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721546     DOI: 10.1016/j.jpsychires.2012.05.001

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  43 in total

1.  High loading of polygenic risk in cases with chronic schizophrenia.

Authors:  S M Meier; E Agerbo; R Maier; C B Pedersen; M Lang; J Grove; M V Hollegaard; D Demontis; B B Trabjerg; C Hjorthøj; S Ripke; F Degenhardt; M M Nöthen; D Rujescu; W Maier; T Werge; O Mors; D M Hougaard; A D Børglum; N R Wray; M Rietschel; M Nordentoft; P B Mortensen; M Mattheisen
Journal:  Mol Psychiatry       Date:  2015-09-01       Impact factor: 15.992

Review 2.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

Review 3.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

4.  Development of a nomogram for the estimation of long-term adherence to clozapine therapy using neutrophil fluorescence.

Authors:  W H Man; A Pérez-Pitarch; I Wilting; E R Heerdink; W W van Solinge; A C G Egberts; A D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2018-04-02       Impact factor: 4.335

5.  Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

Authors:  José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-28       Impact factor: 5.270

Review 6.  Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Authors:  Chen-Chung Liu; Hiroyoshi Takeuchi
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

7.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

8.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

9.  Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.

Authors:  María José Morlán-Coarasa; María Teresa Arias-Loste; Víctor Ortiz-García de la Foz; Obdulia Martínez-García; Carmen Alonso-Martín; Javier Crespo; Manuel Romero-Gómez; Emilio Fábrega; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2016-09-12       Impact factor: 4.530

10.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.